AbbVie Inc. Dividend History (ABBV)
AbbVie Inc. will distribute a dividend of $1.64 per share on February 14, 2025 (67 days)
🤑 AbbVie Inc. has distributed a total of 48 dividends from 2013 to 2024
📈 During this 12 period their dividend has seen a 287.50% increase in the payout amount
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company that focuses on developing innovative therapies for some of the world's most challenging health conditions. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie has quickly established itself in the pharmaceutical industry. The company is headquartered in North Chicago, Illinois. As of the latest update, AbbVie's CEO is Richard A. Gonzalez, who has been instrumental in guiding the company to significant growth and development. In 2022, AbbVie reported annual revenues of approximately $58 billion, driven by its strong portfolio of products, including the widely known immunology drug Humira and cancer treatment Imbruvica. AbbVie is committed to research and development, investing heavily in creating solutions for chronic diseases like immunology, oncology, neuroscience, and ophthalmology. Their innovative approach aims to improve the lives of patients worldwide, making AbbVie a key player in the global healthcare sector.
The cancer monoclonal antibodies market is projected to grow at a CAGR of 18.4% to reach $337.92 billion by 2031, driven by the high incidence of cancer and advancements in biotechnology. The rising use of combination therapies and biosimilars is also expected to create new opportunities for companies in this market.
Benzinga · Published on Mon Dec 09 2024Roche's Polivy in combination with R-CHP has shown positive long-term results in treating first-line diffuse large B-cell lymphoma, with a trend towards improved overall survival and fewer subsequent treatments needed compared to the standard R-CHOP regimen.
GlobeNewswire Inc. · Published on Sun Dec 08 2024Epcoritamab, a T-cell engaging bispecific antibody, in combination with lenalidomide and rituximab (R2) demonstrated high response rates in a clinical trial of patients with relapsed or refractory follicular lymphoma, with an overall response rate of 96% and a complete response rate of 87%.
GlobeNewswire Inc. · Published on Sun Dec 08 2024Previous Payouts (48)
The most recent dividend AbbVie Inc. paid out was on November 15, 2024 (24 days ago) for $1.55 per share
Pay Date | Amount |
---|---|
November 15, 2024 | $1.55 |
August 15, 2024 | $1.55 |
May 15, 2024 | $1.55 |
February 15, 2024 | $1.55 |
November 15, 2023 | $1.48 |
August 15, 2023 | $1.48 |
May 15, 2023 | $1.48 |
February 15, 2023 | $1.48 |
November 15, 2022 | $1.41 |
August 15, 2022 | $1.41 |
May 16, 2022 | $1.41 |
February 15, 2022 | $1.41 |
November 15, 2021 | $1.3 |
August 16, 2021 | $1.3 |
May 14, 2021 | $1.3 |
February 16, 2021 | $1.3 |
November 16, 2020 | $1.18 |
August 14, 2020 | $1.18 |
May 15, 2020 | $1.18 |
February 14, 2020 | $1.18 |
November 15, 2019 | $1.07 |
August 15, 2019 | $1.07 |
May 15, 2019 | $1.07 |
February 15, 2019 | $1.07 |
November 15, 2018 | $0.96 |
August 15, 2018 | $0.96 |
May 15, 2018 | $0.96 |
February 15, 2018 | $0.71 |
November 15, 2017 | $0.64 |
August 15, 2017 | $0.64 |
May 15, 2017 | $0.64 |
February 15, 2017 | $0.64 |
November 15, 2016 | $0.57 |
August 15, 2016 | $0.57 |
May 16, 2016 | $0.57 |
February 16, 2016 | $0.57 |
November 14, 2015 | $0.51 |
August 14, 2015 | $0.51 |
May 15, 2015 | $0.51 |
February 13, 2015 | $0.49 |
November 17, 2014 | $0.42 |
August 15, 2014 | $0.42 |
May 15, 2014 | $0.42 |
February 14, 2014 | $0.4 |
November 15, 2013 | $0.4 |
August 15, 2013 | $0.4 |
May 15, 2013 | $0.4 |
February 15, 2013 | $0.4 |
Dividend data last updated Mon, 09 Dec 2024 14:25:56 GMT UTC